Dr. Manning has developed a proprietary diagnostic tool using PET scans to determine if cancers express ASCT2, allowing the identification of candidates for treatment with ASCT2 inhibitors 

Image A shows a CT scan of cancer tumor in a
mouse lung. Image B shows a PET scan of the
tumor that reveals in blue the expression of ASCT2.
Image C superimposes both images showing the
tumor highlighted for expression of ASCT2.
ASCT2 CDx can be adapted to finding other cancer attributes important for optimal clinical management. Developing a companion diagnostic (CDx) that identifies patients who are most likely to respond to a particular drug is crucial in targeted therapies and personalized medicine.

Developing a companion diagnostic (CDx) that identifies patients who are likely respond to a particular drug is crucial in targeted therapies and personalized medicine.   

Identify Patients

ASCT2 CDx identifies patients likely to respond to ASCT2 inhibitors

Broad Applicability

ASCT2 CDx can be adapted to identify patients likely to respond to other cancer therapeutics

Large Market

CDx is a $4B annual business with 90% of CDx in oncology.